SHANGHAI, China and PLANEGG/ MUNICH, Germany , Jan. 25, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB ), and MorphoSys (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety,